Laboratory of Nutritional Biochemistry, National Institute of Gastroenterology-Research Hospital, Castellana Grotte, Italy.
Ambulatory of Clinical Nutrition, National Institute of Gastroenterology-Research Hospital, Castellana Grotte, Italy.
Anticancer Res. 2019 Nov;39(11):6035-6039. doi: 10.21873/anticanres.13809.
BACKGROUND/AIM: Low-density lipoproteins (LDL) are a heterogeneous class of particles that differ in size and density from each other. Small dense LDL (sdLDL) particles are considered more atherogenic than larger particles. The aim of the study was to evaluate serum levels of sdLDL in patients who died from cardiovascular diseases (CVD) or cancer in a cohort of patients followed up in the De Bellis Research Hospital for 20 years.
A total of 75 participants who died of cancer and 87 who died of CVD were enrolled and they were matched for age and sex with 135 healthy controls, i.e. without CVD or cancer and are still alive.
Patients who died from cancer had the highest value of LDL IV subfraction (0.25±1.16), followed by those who died from CVD (0.17±0.96).
The integrated profile of sdLDL between CVD and cancer suggests that therapeutic modulation of sdLDL may be associated with a risk reduction for these diseases.
背景/目的：低密度脂蛋白（LDL）是一类异质颗粒，彼此在大小和密度上存在差异。小而密的 LDL（sdLDL）颗粒比大颗粒更具致动脉粥样硬化性。本研究旨在评估在德贝利斯研究医院随访 20 年的患者队列中，死于心血管疾病（CVD）或癌症的患者的血清 sdLDL 水平。
共纳入 75 例死于癌症的患者和 87 例死于 CVD 的患者，并按年龄和性别与 135 例无 CVD 或癌症且仍存活的健康对照者匹配。
死于癌症的患者 LDL IV 亚组份的数值最高（0.25±1.16），其次是死于 CVD 的患者（0.17±0.96）。
CVD 和癌症之间 sdLDL 的综合特征表明，sdLDL 的治疗调节可能与这些疾病的风险降低相关。
